Affordable Access

Mycobacterium leprae is naturally resistant to PA-824.

Authors
  • Manjunatha, Ujjini H
  • Lahiri, Ramanuj
  • Randhawa, Baljit
  • Dowd, Cynthia S
  • Krahenbuhl, James L
  • Barry, Clifton E 3rd
Type
Published Article
Journal
Antimicrobial agents and chemotherapy
Publication Date
Oct 01, 2006
Volume
50
Issue
10
Pages
3350–3354
Identifiers
PMID: 17005816
Source
Medline
License
Unknown

Abstract

Leprosy responds very slowly to the current multidrug therapy, and hence there is a need for novel drugs with potent bactericidal activity. PA-824 is a 4-nitroimidazo-oxazine that is currently undergoing phase I clinical trials for the treatment of tuberculosis. The activity of PA-824 against Mycobacterium leprae was tested and compared with that of rifampin in axenic cultures, macrophages, and two different animal models. Our results conclusively demonstrate that PA-824 has no effect on the viability of M. leprae in all three models, consistent with the lack of the nitroimidazo-oxazine-specific nitroreductase, encoded by Rv3547 in the M. leprae genome, which is essential for activation of this molecule.

Report this publication

Statistics

Seen <100 times